Thomas O Cleveland

US Patent:

20220313698, Oct 6, 2022

Filed:

Aug 13, 2020

Appl. No.:

16/992675

Inventors:

- Boston MA, US
Corey Don Anderson - Brighton MA, US
Brett C. Bookser - San Diego CA, US
Brett B. Busch - San Diego CA, US
Jeremy J. Clemens - San Diego CA, US
Thomas Cleveland - San Marcos CA, US
Timothy Richard Coon - Carlsbad CA, US
Bryan Frieman - La Jolla CA, US
Senait G. Ghirmai - San Diego CA, US
Peter Grootenhuis - Del Mar CA, US
Anton V. Gulevich - San Diego CA, US
Sara Sabina Hadida Ruah - La Jolla CA, US
Yoshihiro Ishihara - San Diego CA, US
Haripada Khatuya - San Diego CA, US
Jason McCartney - Cardiff by the Sea CA, US
Mark Thomas Miller - Rancho Santa Fe CA, US
Prasuna Paraselli - San Diego CA, US
Fabrice Pierre - La Jolla CA, US
Andreas Termin - Encinitas CA, US
Sara E. Swift - San Diego CA, US
Johnny Uy - San Diego CA, US
Carl V. Vogel - Carlsbad CA, US
Jinglan Zhou - San Diego CA, US

International Classification:

A61K 31/529
A61K 31/404
A61K 31/47
A61K 31/4418
A61K 31/439
C07D 513/22

Abstract:

This disclosure provides modulators of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), pharmaceutical compositions containing at least one such modulator, methods of treatment of cystic fibrosis using such modulators and pharmaceutical compositions, and processes for making such modulators.

US Patent:

20210047323, Feb 18, 2021

Filed:

Aug 13, 2020

Appl. No.:

16/992441

Inventors:

- Boston MA, US
Kevin J. Gagnon - Acton MA, US
Jicong Li - Cambridge MA, US
Jennifer Lu - San Diego CA, US
Ales Medek - Winchester MA, US
Muna Shrestha - Belmont MA, US
Michael Waldo - Grafton MA, US
Beili Zhang - San Diego CA, US
Carl L. Zwicker - Wakefield MA, US
Corey Don Anderson - Brighton MA, US
Jeremy J. Clemens - San Diego CA, US
Thomas Cleveland - San Marcos CA, US
Timothy Richard Coon - Carlsbad CA, US
Bryan Frieman - La Jolla CA, US
Peter Grootenhuis - Del Mar CA, US
Sara Sabina Hadida Ruah - La Jolla CA, US
Jason McCartney - Cardiff by the Sea CA, US
Mark Thomas Miller - Rancho Santa Fe CA, US
Prasuna Paraselli - San Diego CA, US
Fabrice Pierre - La Jolla CA, US
Sara E. Swift - San Diego CA, US
Jinglan Zhou - San Diego CA, US

International Classification:

C07D 471/08

Abstract:

Crystalline forms of Compound I:pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

US Patent:

20170196862, Jul 13, 2017

Filed:

Oct 6, 2015

Appl. No.:

14/876525

Inventors:

Mark Thomas Miller - Boston MA, US
Corey Anderson - Boston MA, US
Vijayalaksmi Arumugam - Boston MA, US
Brian Richard Bear - Boston MA, US
Hayley Marie Binch - Boston MA, US
Jeremy J. Ciemens - Boston MA, US
Thomas Cleveland - Boston MA, US
Erica Conroy - Boston MA, US
Timothy Richard Coon - Boston MA, US
Bryan A. Frieman - Boston MA, US
Peter Diederik Jan Grootenhuis - Boston MA, US
Raymond Stanley Gross - Boston MA, US
Haripada Khatuya - Boston MA, US
Pramod Virupax Joshi - Boston MA, US
Paul John Krenitsky - Boston MA, US
Chun-Chieh Lin - Boston MA, US
Gulin Erdogan Marelius - Boston MA, US
Vito Melillo - Boston MA, US
Jason McCartney - Boston MA, US
Georgia McGaughey Nicholls - Boston MA, US
Fabrice Jean Denis Pierre - Boston MA, US
Alina Silina - Boston MA, US
Andreas P. Termin - Boston MA, US
Johnny Uy - Boston MA, US
Jinglan Zhou - Boston MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Boston MA

International Classification:

A61K 31/506
A61K 31/4418
A61K 31/444
A61K 31/44
C07D 213/84
C07D 231/14
A61K 31/415
C07D 209/42
A61K 31/404
C07D 401/12
A61K 31/4439
C07D 401/14
C07D 231/12
A61K 31/497
C07D 417/12
C07D 405/14
A61K 31/4545
A61K 31/4709
A61K 31/496
A61K 31/4525
A61J 1/03
C07D 213/82

Abstract:

The present invention features a compound of formula I:or a pharmaceutically acceptable salt thereof, where R, R, R, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.